How to prevent and manage arterial hypertension after heart transplantation

References

1. Matthew R. Weir, Ellen D. Burgess, James E. Cooper, Andrew Z. Fenves, David Goldsmith, Dianne McKay, Anita Mehrotra, Mark M. Mitsnefes, Domenic A. Sica, Sandra J. Taler – Assessment and management of hypertension in transplant patients, J Am Soc Nephrol, 2015; 26: 1248-1260. DOI: 10.1681/ASN.2014080834
2. Ewout J. Hoorn, Stephen B. Walsh, James A. McCormick Robert Zietse, Robert J. Unwin, David H. Ellison – Pathogenesis of calcineurin inhibitor-induced hypertension, J Nephrol, 2012; 25(3): 269-275. DOI: 10.5301/jn.5000174
3. Lucas S. Aparicio, José Alfie, Jessica Barochiner, Paula E. Cuffaro, Marcelo Rada, Margarita Morales, Carlos Galarza, and Gabriel D. Waisman – Hypertension: The neglected complication of transplantation, ISRN Hypertension, 2013; 165937: 1-10. DOI: 10.5402/2013/165937
4. J.D. de Souza-Neto, I.M. de Oliveira, H.A. Lima-Rocha, J.W. Oliveira-Lima, F. Bacal – Hypertension and arterial stiffness in heart transplantation patients, Clinics, 2016; 71(9) 494-499. DOI: 10.6061/clinics/2016(09)02
5. F. Stucker, D. Ackermann - Immunosuppressive drugs— how they work, their side effects and interactions, Therapeutische Umschau, 2011; 68 (12): 679–686
6. G. Heinze, C. Mitterbauer, H. Regele et al. - Angiotensin- converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and gra survival a er renal transplantation, Journal of the Ameri- can Society of Nephrology, 2006; 17(3): 889–899
7. S. Hiremath, D. Fergusson, S. Doucette, A. V. Mulay, G. A. Knoll - Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence, American Journal of Transplantation, vol. 7, no. 10, pp. 2350–2360, 2007.
8. S. C. Textor, L. Schwartz, D. J. Wilson et al., “Systemic and renal e ects of nifedipine in cyclosporine-associated hypertension,” Hypertension, vol. 23, no. 1, supplement, pp. I220–I224, 1994.
9. S. J. Taler, S. C. Textor, V. J. Canzanello et al., “Hypertension a er liver transplantation. A predictive role for pretreatment hemodynamics and e ects of isradipine on the systemic and renal circulations,” American Journal of Hypertension, vol. 13, no. 3, pp. 231–239, 2000.
10. G. Mourad, J. Ribstein, and A. Mimran, “Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants,” Kidney International, vol. 43, no. 2, pp. 419– 425, 1993.
11. K. Midtvedt, A. Hartmann, A. Foss et al. - Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril, Transplantation, 2001; 72(11), 1787–1792
12. T.Mehrens,S. Thiele, B.Suwelack, M.Kempkes, H.Hohage - The beneficial effects of calcium channel blockers on long-term kidney transplant survival are independent of blood-pressure reduction, Clinical Transplantation, 200; 14(3): 257–261
13. K. Kosuge, Y. Jun, H. Watanabe, M. Kimura, M. Nishimoto, T. Ishizaki et al.- Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status, Drug Metabolism and Disposition, 2001; 29(10): 1284–1289
14. Y. H. Wang, D. R. Jones, S. D. Hall - Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil, Drug Metabolism and Disposition, 2005; 33(5): 664– 671
15. M. Hausberg, M. Barenbrock, H. Hohage, S. MÜller, S. Heidenreich, and K. H. Rahn - ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allogra recipients, Hypertension, 1999; 33(3): 862–868
16. A. A. Hernandez, B. Baye ́s, V. Cabello et al., “Tratamiento de la Hipertension Arterial Postrasplante Renal,” Nefrologia, vol. 29, no. 3, pp. 16–23, 2009
17. Frans H.H. Leenen, Elizabeth Coletta, Ross A. Davies – Prevention of Renal Dysfunction and Hypertension by Amlodipine after Heart Transplantation, Am J Cardiology, 2007; 100: 531-535. DOI: 10.1016/j.amjcard.2007.03.058